tiprankstipranks
Tenax Therapeutics (TENX)
NASDAQ:TENX
US Market
Want to see TENX full AI Analyst Report?

Tenax Therapeutics (TENX) Stock Forecast & Price Target

712 Followers
See the Price Targets and Ratings of:

TENX Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Tenax
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TENX Stock 12 Month Forecast

Average Price Target

$9.00
▼(-38.06% Downside)
Based on 10 Wall Street analysts offering 12 month price targets for Tenax Therapeutics in the last 3 months. The average price target is $9.00 with a high forecast of $35.00 and a low forecast of $4.00. The average price target represents a -38.06% change from the last price of $14.53.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","36":"$36","11.25":"$11.25","19.5":"$19.5","27.75":"$27.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11.25,19.5,27.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,15.338461538461537,16.976923076923075,18.615384615384613,20.253846153846155,21.89230769230769,23.53076923076923,25.16923076923077,26.807692307692307,28.446153846153845,30.084615384615383,31.72307692307692,33.36153846153846,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,13.338461538461537,12.976923076923077,12.615384615384615,12.253846153846153,11.892307692307693,11.53076923076923,11.169230769230769,10.807692307692307,10.446153846153846,10.084615384615384,9.723076923076924,9.361538461538462,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,12.953846153846154,12.207692307692307,11.461538461538462,10.715384615384615,9.96923076923077,9.223076923076924,8.476923076923077,7.730769230769231,6.984615384615385,6.2384615384615385,5.492307692307692,4.746153846153847,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.19,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$35.00Average Price Target$9.00Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on TENX
Piper Sandler
Piper Sandler
$14
Buy
-3.65%
Downside
Reiterated
08/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on TENX
Leerink Partners
Leerink Partners
$26$4
Buy
-72.47%
Downside
Reiterated
08/11/26
Tenax Therapeutics price target lowered to $4 from $26 at LeerinkTenax Therapeutics price target lowered to $4 from $26 at Leerink
Guggenheim
$40$4
Buy
-72.47%
Downside
Reiterated
08/11/26
Tenax Therapeutics price target lowered to $4 from $40 at GuggenheimTenax Therapeutics price target lowered to $4 from $40 at Guggenheim
Canaccord Genuity Analyst forecast on TENX
Canaccord Genuity
Canaccord Genuity
$35$4
Buy
-72.47%
Downside
Reiterated
08/11/26
Tenax Therapeutics price target lowered to $4 from $35 at CanaccordTenax Therapeutics price target lowered to $4 from $35 at Canaccord
Chardan Capital Analyst forecast on TENX
Gautam Chukka
Chardan Capital
Not Ranked
Chardan Capital
$27$5
Hold
-65.59%
Downside
Downgraded
08/11/26
Tenax Therapeutics downgraded to Neutral from Buy at ChardanTenax Therapeutics downgraded to Neutral from Buy at Chardan
Evercore ISI
$39$5
Hold
-65.59%
Downside
Downgraded
08/10/26
Tenax Therapeutics downgraded to In Line from Outperform at Evercore ISITenax Therapeutics downgraded to In Line from Outperform at Evercore ISI
William Blair Analyst forecast on TENX
William Blair
William Blair
Hold
Downgraded
08/10/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Tenax Therapeutics (NASDAQ: TENX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
LifeSci Capital Analyst forecast on TENX
LifeSci Capital
LifeSci Capital
$35$5
Buy
-65.59%
Downside
Reiterated
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX) and Cogent Biosciences (NASDAQ: COGT)
Roth MKM
$30$5
Buy
-65.59%
Downside
Reiterated
08/10/26
Tenax Therapeutics price target lowered to $5 from $30 at Roth CapitalTenax Therapeutics price target lowered to $5 from $30 at Roth Capital
Cantor Fitzgerald Analyst forecast on TENX
Cantor Fitzgerald
Cantor Fitzgerald
$35
Buy
140.88%
Upside
Reiterated
07/29/26
Analysts Offer Insights on Healthcare Companies: uniQure (NASDAQ: QURE) and Tenax Therapeutics (NASDAQ: TENX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on TENX
Piper Sandler
Piper Sandler
$14
Buy
-3.65%
Downside
Reiterated
08/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on TENX
Leerink Partners
Leerink Partners
$26$4
Buy
-72.47%
Downside
Reiterated
08/11/26
Tenax Therapeutics price target lowered to $4 from $26 at LeerinkTenax Therapeutics price target lowered to $4 from $26 at Leerink
Guggenheim
$40$4
Buy
-72.47%
Downside
Reiterated
08/11/26
Tenax Therapeutics price target lowered to $4 from $40 at GuggenheimTenax Therapeutics price target lowered to $4 from $40 at Guggenheim
Canaccord Genuity Analyst forecast on TENX
Canaccord Genuity
Canaccord Genuity
$35$4
Buy
-72.47%
Downside
Reiterated
08/11/26
Tenax Therapeutics price target lowered to $4 from $35 at CanaccordTenax Therapeutics price target lowered to $4 from $35 at Canaccord
Chardan Capital Analyst forecast on TENX
Gautam Chukka
Chardan Capital
Not Ranked
Chardan Capital
$27$5
Hold
-65.59%
Downside
Downgraded
08/11/26
Tenax Therapeutics downgraded to Neutral from Buy at ChardanTenax Therapeutics downgraded to Neutral from Buy at Chardan
Evercore ISI
$39$5
Hold
-65.59%
Downside
Downgraded
08/10/26
Tenax Therapeutics downgraded to In Line from Outperform at Evercore ISITenax Therapeutics downgraded to In Line from Outperform at Evercore ISI
William Blair Analyst forecast on TENX
William Blair
William Blair
Hold
Downgraded
08/10/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Tenax Therapeutics (NASDAQ: TENX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
LifeSci Capital Analyst forecast on TENX
LifeSci Capital
LifeSci Capital
$35$5
Buy
-65.59%
Downside
Reiterated
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX) and Cogent Biosciences (NASDAQ: COGT)
Roth MKM
$30$5
Buy
-65.59%
Downside
Reiterated
08/10/26
Tenax Therapeutics price target lowered to $5 from $30 at Roth CapitalTenax Therapeutics price target lowered to $5 from $30 at Roth Capital
Cantor Fitzgerald Analyst forecast on TENX
Cantor Fitzgerald
Cantor Fitzgerald
$35
Buy
140.88%
Upside
Reiterated
07/29/26
Analysts Offer Insights on Healthcare Companies: uniQure (NASDAQ: QURE) and Tenax Therapeutics (NASDAQ: TENX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tenax Therapeutics

3 Months
David RisingerLeerink Partners
Success Rate
7/9 ratings generated profit
78%
Average Return
+19.70%
Copying David Risinger's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +19.70% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
7/9 ratings generated profit
78%
Average Return
+61.86%
Copying David Risinger's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +61.86% per trade.
2 Years
Success Rate
2/8 ratings generated profit
25%
Average Return
-25.54%
Copying Jonathan Aschoff's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -25.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TENX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
5
9
8
13
17
Buy
5
6
5
4
3
Hold
0
0
0
0
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
15
13
17
22
In the current month, TENX has received 20 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. TENX average Analyst price target in the past 3 months is 9.00.
Each month's total comprises the sum of three months' worth of ratings.

TENX Financial Forecast

TENX Earnings Forecast

Next quarter’s earnings estimate for TENX is -$0.36 with a range of -$0.39 to -$0.33. The previous quarter’s EPS was -$0.35. TENX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TENX has Performed in-line its overall industry.
Next quarter’s earnings estimate for TENX is -$0.36 with a range of -$0.39 to -$0.33. The previous quarter’s EPS was -$0.35. TENX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TENX has Performed in-line its overall industry.
No data currently available

TENX Sales Forecast

Next quarter’s sales forecast for TENX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TENX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TENX has Performed in-line its overall industry.
Next quarter’s sales forecast for TENX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TENX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TENX has Performed in-line its overall industry.

TENX Stock Forecast FAQ

What is TENX’s average 12-month price target, according to analysts?
Based on analyst ratings, Tenax Therapeutics’s 12-month average price target is 9.00.
    What is TENX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for TENX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is TENX a Buy, Sell or Hold?
        Tenax Therapeutics has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
          What is Tenax Therapeutics’s price target?
          The average price target for Tenax Therapeutics is 9.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $35.00 ,the lowest forecast is $4.00. The average price target represents -38.06% Decrease from the current price of $14.53.
            What do analysts say about Tenax Therapeutics?
            Tenax Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
              How can I buy shares of TENX?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.